The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study
- 19 November 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 42 (18) , 1728-1738
Abstract
Aims : The aim of this study was to evaluate the temporal pattern of amputations in patients with type 2 diabetes mellitus (T2DM), the risk of amputations by new and older anti-diabetic drugs (ADDs), and the interplay of peripheral artery disease (PAD) with therapy and amputation risk. Methods and results : Using Centricity Electronic Medical Records from USA, 3 293 983 patients with T2DM were identified: 169 739 received sodium-glucose cotransporter type-2 inhibitors (SGLT-2i; no exposure to incretins); 149 826 received glucagon-like peptide 1 receptor agonists [GLP-1RA, no SGLT-2i or dipeptidyl peptidase-4 inhibitor (DPP-4i) exposure]; 448 225 received DPP-4i (no exposure to GLP-1RA or SGLT-2i); and 1 954 353 received other ADDs. The proportion of incident amputations per 10 000 adults ranged between 4.7 and 6.8 during 2000–08 and significantly increased to 12.3 in 2017. Over 17 211 719 person-years follow-up post T2DM diagnosis, the rates per 1000 person-years of any and lower limb amputations (LLAs) were similar between SGLT-2i and incretins [95% confidence interval (CI) range: 1.06–1.67], and significantly higher in other groups (95% CI range: 1.96–2.29). In propensity score-adjusted pairwise analyses, the risk of LLA was not higher in SGLT-2i vs. GLP1-RA [hazard ratio (HR) (95% CI): 0.88 (0.73, 1.05)], and lower in SGLT-2i vs. DPP-4i/other ADD [HR (95% CI): 0.65 (0.56, 0.75)/0.43 (0.37, 0.49)]. The rate of LLA was similar in patients treated with canagliflozin, empagliflozin, or dapagliflozin. Patients with PAD had more than four-fold higher LLA risk (range of 95% CI of HR: 3.6–6.0). Conclusion : The risk of amputation in patients treated with SGLT-2i and incretins was not higher compared with other ADDs. Pre-existing PAD was the greatest driver of amputation risk.Keywords
Funding Information
- National Health and Medical Research Council
- Australian Government’s National Collaborative Research Infrastructure Strategy
- Therapeutic Innovation Australia
This publication has 31 references indexed in Scilit:
- Long-term Trends in Antidiabetes Drug Usage in the U.S.: Real-world Evidence in Patients Newly Diagnosed With Type 2 DiabetesDiabetes Care, 2017
- Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium‐glucose co‐transporter‐2 inhibitors in the USA: A retrospective cohort studyDiabetes, Obesity and Metabolism, 2017
- Incidence of lower extremity amputations in the diabetic compared with the non-diabetic population: A systematic reviewPLOS ONE, 2017
- Canagliflozin and Cardiovascular and Renal Events in Type 2 DiabetesNew England Journal of Medicine, 2017
- Data Mining Approach to Estimate the Duration of Drug Therapy from Longitudinal Electronic Medical RecordsThe Open Bioinformatics Journal, 2017
- Impact of hypoglycemic events and HbA1c level on sulfonylurea discontinuation and down-titrationExpert Review of Pharmacoeconomics & Outcomes Research, 2016
- Progression to insulin therapy among patients with type 2 diabetes treated with sitagliptin or sulphonylurea plus metformin dual therapyDiabetes, Obesity and Metabolism, 2015
- Changes in Diabetes-Related Complications in the United States, 1990–2010New England Journal of Medicine, 2014
- Six‐month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care settingDiabetes, Obesity and Metabolism, 2009
- Assessment of Cardiometabolic Risk Factors in a National Primary Care Electronic Health Record DatabaseValue in Health, 2007